← board
OGEN
Oragenics, Inc.distress 4/10 · elevated risk$0.53+0%today-63% from 52w high
Lead: concussion/mild traumatic brain injury
Revenue
pre-revenue
Liquidity
$10M
Runway
1.1 yrs
Shares 1y
+9%
Price & events
-42.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
-5.0%
1W
-9.8%
1M
-15.6%
3M
-38.1%
6M
-63.1%
1Y
-98.3%
2Y
-100.0%
5Y
-99.9%
All
Overview
- Market Cap
- $2.40M
- Volume
- 5.13K
- 52 Week Range
- $0.50 – $1.44
- Total Shares
- 4.51M
- Float Shares
- 4.42M
- Short %
- 17.20%
- % Held by Insiders
- 1.93%
- % Held by Institutions
- 5.76%
- RVOL
- 0.14x
- Beta
- 1.25
Pipeline stages · 1 programs
Neurosteroid enantiomer
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-01-01 | Phase 2 | Neurosteroid enantiomer | Mild Traumatic Brain Injury, Concussion | 40 | not yet recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 16
- 2026Guided 40%readoutPhase 2ONP-002 · Data readout from Australia Phase IIa trialsSEC 8-K
- Q4 2026Guided 70%trial initiationsecondaryPhase 2ONP-002 · Phase IIb trial initiation in USSEC 8-K
- Q4 2026Guided 70%regulatory submissionFiled (NDA/BLA)ONP-002 · IND submission to FDA targeting Q4 2026 for next phase.SEC 8-K
- Q3 2026Guided 70%readoutPhase 2ONP-002 · Phase IIa data readoutSEC 8-K
- second quarter of 2026filing acceptanceFiled (NDA/BLA)ONP-002 · Type C Meeting Request submission to FDA.SEC 8-K
- second quarter of 2026trial initiationsecondaryPhase 2ONP-002 · Activation of two additional clinical sites (Alfred Hospital and Royal Adelaide Hospital) expected in Q2 2026.SEC 8-K
- June 29, 2026conferencedata presentationsecondaryAnnual Shareholder Meeting.SEC 8-K
- 2026-05-18safety signalONP-002 · Zero serious adverse events recorded in ongoing Phase IIa trial.SEC 8-K
- 2026-05-18partnershipSigned Letter of Intent to pursue licensing agreement for a complementary CNS-related medical device.SEC 8-K
- 2026-05-07partnershipCardioDialysis · Signed LOI to license CardioDialysis technology for TBI and neurodegenerative diseases.SEC 8-K
- March 31, 2026trial initiationsecondaryPhase 2ONP-002 · Mackay Base Hospital site activated and first patient dosed.SEC 8-K
- Q3-Q4 2025regulatory submissionFiled (NDA/BLA)ONP-002 · IND submission to FDA for Phase IIb clinical trialSEC 8-K
- Q3 2025trial initiationsecondaryPhase 2ONP-002 · Phase IIa clinical trial launchSEC 8-K
- Q3 2025regulatory submissionFiled (NDA/BLA)ONP-002 · Submission of IND package for Phase IIb trial in USSEC 8-K
- end of Q1 2025 or early Q2 2025trial initiationsecondaryPhase 2ONP-002 · First patient dosed in Phase II clinical trial in AustraliaSEC 8-K
- Q1 2025regulatory submissionFiled (NDA/BLA)ONP-002 · Submission of IB package for Phase II trial in AustraliaSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — concussion/mild traumatic brain injury
- none identified
Recent news
- 2026-07-20Ogen posted as JS, Home & Political Department, in Assam (UPDATED) - Whispers In The Corridors
- 2026-07-15Oragenics Inc. (OGEN) Holds Near Support Amid Modest Decline - Equity Put Call - dars.gov.et
- 2026-07-13OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Despite Stock Decline - Earnings Weakness Phase - dars.gov.et
- 2026-07-10Oragenics Inc - to Receive Exclusive License - Moomoo
- 2026-07-07Oragenics (OGEN) CFO receives 55,900 stock options at $0.59 exercise price - Stock Titan
- 2026-07-07ORAGENICS (OGEN) CFO reports initial holdings, including 10,000-share stock option grant - Stock Titan
- 2026-07-07Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - GlobeNewswire
- 2026-07-07Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.